Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Fujisawa selects orally active fibrinogen antagonist for clinical studies

March 20, 1997

Meiji Seika's new orally active gpIIb/IIIa antagonist

March 20, 1997

Mitsui Toatsu reveals orally active antiplatelet agent

March 20, 1997

InTIME trial indicates nPA superior to tPA in MI

March 19, 1997

Aggrastat prevents heart attack, death and other complications in unstable angina

March 19, 1997

PGI2 agonists described by Fujisawa

March 19, 1997

Roberts' Agrylin approved by FDA

March 18, 1997

New clot buster comparable to t-PA in AMI

March 18, 1997

Pharmacodynamic effects of xemilofiban in cirrhotics

March 18, 1997

Taisho claims orally active antiplatelet agents

March 18, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...